New daily pill shows promise for weight loss in early trial

NCT ID NCT07002905

Completed Disease control Sponsor: Ascletis Pharma (China) Co., Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase IIa study tested a daily pill called ASC30 in 125 adults with obesity or overweight who also had weight-related health problems. The goal was to see if the drug helps with weight loss and is safe. Participants received either ASC30 or a placebo for up to 13 weeks, and researchers measured changes in body weight, waist size, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASC30 tablets
What this could lead to: If successful, this could lead to a new daily pill for weight loss in people with obesity or overweight.
What could go wrong: This is an early Phase IIa trial with only 125 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC WEIGHT MANAGEMENT

Contacts and locations

Locations

Ascletis Clinical Site

Rogers, Arkansas, 72758, United States
Ascletis Clinical Site

Fort Myers, Florida, 33912, United States
Ascletis Clinical Site

Miami, Florida, 33172, United States
Ascletis Clinical Site

Columbus, Ohio, 43212, United States
Ascletis Clinical Site

Bellaire, Texas, 77401, United States
Ascletis Clinical Site

San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.